Business Standard

Bharat Biotech inks pact to commercialise Covid-19 vaccine Covaxin in US

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA

Sohini Das
Bharat Biotech’s Covid-19 vaccine Covaxin would soon be available in the US market after the firm announced a tie-up with biopharmaceutical company Ocugen to commercialise it for US.

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases.

It will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including EUA) and commercialisation for the US market.

Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 02 2021 | 10:13 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com